Hataali updates blockchain-based advanced therapy platform to address pain point
Contract manufacturers, pharma companies, and health service providers need to collaborate to get cell and gene therapies to patients. However, Hataali has seen the stakeholders have disparate systems with little interoperability and insist on using their own specific chain of identity (COI) identifiers. That can create problems.
“When you have different formats, there is a greater risk of confusion and mistakes between all the different partners involved in the treatment process. Also, having many different formats also makes it difficult for the tech systems to communicate and integrate with each other. Remember we are dealing with patients, and if you give the wrong treatment to the wrong patient, it could lead to serious harm or even death of the patient,” said a spokesperson for Hataali.
Hataali has addressed the challenge with its updated platform. Hataali 2.0 supports the use of multiple COIs identifiers to enable stakeholders to monitor the location and condition of individual therapies in real time, regardless of the complexity of the supply chain.
Fully digital platforms automatically check the COI identifier at each scan or transfer in the chain of custody, thereby addressing the challenge of spotting potential inconsistencies. Other companies such as Trakcel and Vineti have their own solutions for the problems but, with its latest update, Hataali thinks it has established an important point of differentiation over rival digital cell and gene therapy supply chain platforms.
“Hataali is the only platform which allows different partners to use their own COI identifiers so that the whole process becomes smoother and faster. It also prevents discussions and disputes as to which CoI identifier formats to use,” said the spokesperson.